Further immunotherapeutic strategies addressing CD33 on AML cells include the bispecific antibody GEM 333, the tandem diabody AMV564 and the CD33xCD3 bispecific antibody JNJ-67571244, respectively, and are currently investigated in phase I clinical trials. The gene discussed is CD33; the disease is acute myeloid leukemia.